Latest News & Updates

18/09/2006
TARGANTA PRESENTS STUDY RESULTS AT ICAAC SHOWING BROAD POTENTIAL OF ORITAVANCIN AGAINST GRAM-POSITIVE PATHOGENS

18/09/2006
TARGANTA APPOINTS MARK LEUCHTENBERGER, FORMER PRESIDENT AND CEO OF THERION BIOLOGICS CORPORATION, AS PRESIDENT AND CEO

24/08/2006
TARAGANTA ANNOUNCES ADDITIONS TO MANAGEMENT TEAM

25/01/2006
TARGANTA APPOINTS WILLIAM CROUSE TO BOARD OF DIRECTORS

27/12/2005
TARGANTA ACQUIRES LATE-STAGE ANTIBIOTIC FROM INTERMUNE

19/12/2005
TARGANTA THERAPEUTICS ANNOUNCES DISCOVERY OF NEW CLASS OF AGENTS TO TARGET STAPHYLOCOCCUS AUREUS

22/07/2005
Advancing the search for new antibacterial agents: Targanta drug discovery platform to be presented at the 45th ICAAC

31/01/2005
Targanta appoints Chief Scientific Officer

27/01/2005
Phagetech announces name change to Targanta Therapeutics

12/01/2004
Bacteriophage genomics approach to antimicrobial drug discovery published by PhageTech in Nature Biotechnology

15/09/2003
Phages Point the Way to Novel Targets for Antimicrobial Drug Discovery; PhageTech Drug Discovery Platform Presented at ICAAC

23/06/2003
Phagetech appoints former Pfizer R&D executive, Pierre Etienne, M.D., President and Chief Executive Officer

19/06/2002
PhageTech Receives US Patent Covering Novel Target and Method of Discovering New Antibiotics to Fight Staph aureus